Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof
Inventors
Kasibhatla, Srinivas Rao • Kalakuntla, Raman Kumar • Weston, Alexis • Thode, Trason • Sharma, Sunil • Kaadige, Mohan R.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12152015-B2
Publication Date
2024-11-26
Expiration Date
Abstract
Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).
Core Innovation
The invention relates to a method for the treatment of cancer in a mammal by administering a therapeutically effective amount of a compound of Formula II. Formula II includes defined structural variables X, Z, W, and multiple substituent and ring definitions R1-R11, with each variable constrained to specified sets of alternatives. The method also covers isomer, hydrate, solvate, polymorph, tautomer, stereoisomer, and pharmaceutically acceptable salt variants of the Formula II compound.
The disclosure frames the treatment of cancer across a wide range of cancer types in a mammal, including solid tumors and other listed cancers. It also describes related quinazoline, quinoline, diazepane, diazabicyclooctane, azepane, sulfonamide, and sulfamide chemotypes in the partial chemical examples. These examples include preparation and characterization of substituted compounds and intermediates connected to the Formula II-defined scaffold.
Claims Coverage
The consolidated independent claim coverage centers on one method claim for treating cancer in a mammal by administering a therapeutically effective amount of a compound of Formula II. The inventive features combine broad cancer indications with extensive structural definition of Formula II through X, Z, W, substituents R1-R11, and ring or bridge relationships, together with pharmaceutically acceptable salts and variant forms.
Cancer treatment by administering a Formula II compound
A method for the treatment of cancer in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of Formula II, where cancer is selected from a broad recited group and Formula II is defined by X, Z, W, and substituents R1-R11 with specified options, including pharmaceutically acceptable salts and isomeric, hydrate, solvate, polymorph, tautomer, and stereoisomer variants.
Formula II structural definition
X is N or CR11, Z is C or N, and W is selected from C1-C5 alkyl, —C(=O)—(CH2)n—, —(C1-C5 alkyl)-N—, NH, and a direct bond. The remaining substituents and ring or bridge relationships are defined within specified sets, including choices for R1, R2, R3, R7, R8, R9, R10, and R11.
Allowed substituent ranges and variant forms
The claim set includes constraints such as n being between 1 and 3, selected halogen and lower alkyl options, and inclusion of pharmaceutically acceptable salts, isomers, hydrates, solvates, polymorphs, and tautomers of the Formula II compound.
Across the independent claim, the inventive scope is a cancer-treatment method in a mammal using a therapeutically effective amount of a Formula II compound with tightly defined structural variables and permitted chemical variants. Dependent claims narrow the structural selections, specific cancer categories, or enumerated compound members.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?